Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
26 août 2020 10h15 HE
|
Ambu A/S
See attached file.
Attachment
1. Reporting of transactions made by persons discharging managerial responsibilities
...
Ambu A/S: Interim report for Q3 2019/20
26 août 2020 01h33 HE
|
Ambu A/S
Ambu delivered 21% organic revenue growth in Q3, driven by an 81% increase in Visualization sales. COVID-19 significantly increased the demand for Ambu’s resuscitators and single-use scopes primarily...
Ambu receives FDA clearance for its sterile, single-use duodenoscope
17 juil. 2020 07h48 HE
|
Ambu A/S
Ambu is ready to launch single-use solution to help increase patient safety and prevent duodenoscope infections. Further devices for GI in development. The Ambu® aScope™ Duodeno received 510(k)...
Ambu A/S: Capital increase in connection with exercise of warrants issued
14 mai 2020 09h36 HE
|
Ambu A/S
Capital increase in connection with exercise of warrants Ambu A/S issued 2,000,000 warrants in 2014, 770,000 warrants in 2015, and 419,500 warrants in November 2016. Each warrant entitles the holder...
Ambu A/S: Interim report for Q2 2019/20 and for the period 1 October 2019 to 31 March 2020
04 mai 2020 11h10 HE
|
Ambu A/S
Accelerating commercial investments in GI and urology after submitting the aScope™ Duodeno for FDA-approval Ambu posted organic growth of 24% in Q2 as COVID-19 pandemic increased the demand for...
Ambu A/S: Interim report for Q2 2019/20 and for the period 1 October 2019 to 31 March 2020
04 mai 2020 11h08 HE
|
Ambu A/S
Accelerating commercial investments in GI and urology after submitting the aScope™ Duodeno for FDA-approval Ambu posted organic growth of 24% in Q2 as COVID-19 pandemic increased the demand for...
Ambu A/S: Ambu reports revenue growth for Q2 and raises the revenue guidance for the year
06 avr. 2020 11h19 HE
|
Ambu A/S
Ambu pre-announces results for Q2 2019/20 with organic revenue growth of 24% and sales of 313,000 single-use endoscopes. On this basis, the guidance for organic revenue growth for the full year is...
Ambu A/S: Ambu’s production exempt from Malaysian movement control order
18 mars 2020 01h51 HE
|
Ambu A/S
The Malaysian authorities have granted Ambu – as a manufacturer of medical devices – exemption from the two-week movement control order that has been declared with effect from 18 March, 2020. The...
Ambu A/S: Malaysian government orders two-week movement control
17 mars 2020 03h55 HE
|
Ambu A/S
With the rise in Covid-19 cases, the Malaysian government has declared that the entire country will be on a movement control order starting 18 March, 2020 and expected to end on 31 March, 2020. Ambu...
Ambu A/S: Capital increase in connection with exercise of warrants issued
12 févr. 2020 10h40 HE
|
Ambu A/S
Ambu announces capital increase.
Attachment
Company_Announcement_no. 6 2019_20
...